Monday June 1, 2020

Sudocrem boss: new skin drug will net €1.5bn

Drug will be used to treat epidermolysis bullosa

10th April, 2016
Iconic brand, Sudocrem Pic: Getty

A new publicly quoted pharmaceutical company backed by Sudocrem founder Dr Ray Stafford is predicting revenues of up to $1.5 billion from one of its drugs, which is used to treat rare genetic skin disorders.

The drug, which is currently going through the approval process, will be used to treat epidermolysis bullosa (EB). In its most severe form, the disease causes infant death, and at its mildest, causes painful and disfiguring blisters through childhood and into...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

The way we did business a few months ago may never return – so the opportunity is to make changes that will both aid recovery and set us up well for our new futures

Tom Maguire | 4 weeks ago

What’s coming up today and what you might have missed

Hannah O’Brien | 5 months ago